Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients with Coronary Artery Disease: ABSORB China Trial

Journal of the American College of Cardiology

Volumn 66, Issue 21, 2015, Pages 2298-2309

  Gao, Runlin ^a   Yang, Yuejin ^a   Han, Yaling ^b   Huo, Yong ^c   Chen, Jiyan ^d   Yu, Bo ^e   Su, Xi ^f   Li, Lang ^g   Kuo, Hai Chien ^h   Ying, Shih Wa ^h   Cheong, Wai Fung ^h   Zhang, Yunlong ^h   Su, Xiaolu ^h   Xu, Bo ^a   Popma, Jeffery J ⁱ   Stone, Gregg W ^j  

^a FUWAI HOSPITAL   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e HARBIN MEDICAL UNIVERSITY   (China)

^f WUHAN ASIA HEART HOSPITAL   (China)

^g GUANGXI MEDICAL UNIVERSITY   (China)

^h ABBOTT VASCULAR   (United States)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^j NewYork Presbyterian Hospital   (United States)

more..

Author keywords

bioresorbable vascular scaffold; everolimus; randomized controlled trial; stent

Indexed keywords

ACETYLSALICYLIC ACID; CHROMIUM; CLOPIDOGREL; COBALT; EVEROLIMUS; TICAGRELOR; METAL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BIORESORBABLE SCAFFOLD; CHINA; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEVICE APPROVAL; DEVICE SAFETY; DIABETES MELLITUS; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCAFFOLD THROMBOSIS; STENT THROMBOSIS; TREATMENT OUTCOME; AGED; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; DRUG ELUTING STENT; MIDDLE AGED; PROSPECTIVE STUDY; RADIOGRAPHY; STANDARDS; STENT; TISSUE SCAFFOLD; TRENDS;

ABSORBABLE IMPLANTS; AGED; CHINA; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METALS; MIDDLE AGED; PROSPECTIVE STUDIES; STENTS; TISSUE SCAFFOLDS; TREATMENT OUTCOME;

EID: 84959001781     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.09.054     Document Type: Article

References (17)

1. S.S. Hu, L.Z. Kong, R.L. Gao, and et al. Outline of the report on cardiovascular disease in China, 2010 Biomed Environ Sci 25 2012 251 256
2. H. Li, and J. Ge Cardiovascular diseases in China: current status and future perspectives IJC Heart &Vascular 6 2015 25 31
3. R. Gao The official launch of AsiaIntervention AsiaIntervention 1 2015 5 7
4. W.S. Pietrzak, M.L. Verstynen, and D.R. Sarver Bioabsorbable fixation devices: status for the craniomaxillofacial surgeon J Craniofac Surg 8 1997 92 96
5. J.C. Middleton, and A.J. Tipton Synthetic biodegradable polymers as orthopedic devices Biomaterials 21 2000 2335 2346
6. D. Robaei, L.M. Back, S.Y. Ooi, M.R. Pitney, and N. Jepson Everolimus-eluting bioresorbable vascular scaffold implantation in real world and complex coronary disease: procedure and 30-day outcomes at two Australian Centers Heart Lung Circ 24 2015 854 859
7. C. Costopoulos, A. Latib, T. Naganuma, and et al. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population Catheter Cardiovasc Interv 85 2015 E10 E15
8. P.W. Serruys, B. Chevalier, D. Dudek, and et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomized controlled trial Lancet 385 2015 43 54
9. D.E. Cutlip, S. Windecker, R. Mehran, et al. for the Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
10. V. Novack, M. Pencina, D.J. Cohen, and et al. Troponin criteria for myocardial infarction after percutaneous coronary intervention Arch Intern Med 172 2012 502 508
11. G.W. Stone, M. Midei, W. Newman, and et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease. A randomized trial JAMA 299 2008 1903 1913
12. L. Mauri, E.J. Orav, S. Candia, and et al. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials Circulation 112 2005 2833 2839
13. L. Mauri, E.J. Orav, and R.E. Kuntz Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison Circulation 111 2005 2335 2342
14. S.J. Pocock, A.J. Lansky, R. Mehran, and et al. Angiographic surrogate end point in drug-eluting stent trials: a systemic evaluation based on individual patient data from 11 randomized, controlled trials J Am Coll Cardiol 51 2008 23 32
15. S. Puricel, D. Arroyo, N. Copataux, and et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds J Am Coll Cardiol 65 2015 791 801
16. J.R. Costa Jr., A. Abizaid, A.L. Bartorelli, et al. for the ABSORB EXTEND Investigators Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the Absorb bioresorbable vascular scaffold EuroIntervention 11 2015 141 148
17. T. Uchida, J. Popma, G.W. Stone, and et al. The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions J Am Coll Cardiol Intv 3 2010 403 411